Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 66 entries
Sorted by: Best Match Show Resources per page
Role of Evaluating MGMT Status and 1p36 Deletion in Radiosurgery-Induced Anaplastic Ependymoma That Rapidly and Completely Resolved by Temozolomide Alone: Case Report and Review of the Literature.

Journal of neurological surgery reports

Hirono S, Iwadate Y, Kambe M, Hiwasa T, Takiguchi M, Nakatani Y, Saeki N.
PMID: 26251808
J Neurol Surg Rep. 2015 Jul;76(1):e43-7. doi: 10.1055/s-0034-1396657. Epub 2015 Jan 16.

Stereotactic gamma knife surgery (GKS)-induced brain tumors are extremely rare, and no ependymal tumors induced by GKS have been reported. Therefore, little is known about their clinical, pathologic, and genetic features. In addition, a regimen of adjuvant chemotherapy for...

Cite
Hirono S, Iwadate Y, Kambe M, et al. Role of Evaluating MGMT Status and 1p36 Deletion in Radiosurgery-Induced Anaplastic Ependymoma That Rapidly and Completely Resolved by Temozolomide Alone: Case Report and Review of the Literature. J Neurol Surg Rep. 2015;76(1):e43-7doi: 10.1055/s-0034-1396657.
Hirono, S., Iwadate, Y., Kambe, M., Hiwasa, T., Takiguchi, M., Nakatani, Y., & Saeki, N. (2015). Role of Evaluating MGMT Status and 1p36 Deletion in Radiosurgery-Induced Anaplastic Ependymoma That Rapidly and Completely Resolved by Temozolomide Alone: Case Report and Review of the Literature. Journal of neurological surgery reports, 76(1), e43-7. https://doi.org/10.1055/s-0034-1396657
Hirono, Seiichiro, et al. "Role of Evaluating MGMT Status and 1p36 Deletion in Radiosurgery-Induced Anaplastic Ependymoma That Rapidly and Completely Resolved by Temozolomide Alone: Case Report and Review of the Literature." Journal of neurological surgery reports vol. 76,1 (2015): e43-7. doi: https://doi.org/10.1055/s-0034-1396657
Hirono S, Iwadate Y, Kambe M, Hiwasa T, Takiguchi M, Nakatani Y, Saeki N. Role of Evaluating MGMT Status and 1p36 Deletion in Radiosurgery-Induced Anaplastic Ependymoma That Rapidly and Completely Resolved by Temozolomide Alone: Case Report and Review of the Literature. J Neurol Surg Rep. 2015 Jul;76(1):e43-7. doi: 10.1055/s-0034-1396657. Epub 2015 Jan 16. PMID: 26251808; PMCID: PMC4521005.
Copy Download .nbib Format: NLM
Clinical response of O(6)-methylguanine-DNA methyltransferase levels to 1,3-(2-chloroethyl)-1-nitrosourea chemotherapy in glioma patients.

Neurosurgical focus

Chen ZP, Yarosh D, Garcia Y, Tampieri D, Mohr G, Langleben A, Panasci LC.
PMID: 17154443
Neurosurg Focus. 1998 Jun 15;4(6):e3. doi: 10.3171/foc.1998.4.4.4.

Adjuvant nitrosourea chemotherapy fails to prolong patient survival significantly as many tumors demonstrate resistance to these drugs. It has been documented in cell lines that O(6)-methylguanine-DNA methyltransferase (MGMT) plays an important role in chloroethylnitrosourea (CENU) drug resistance. The authors...

Cite
Chen ZP, Yarosh D, Garcia Y, et al. Clinical response of O(6)-methylguanine-DNA methyltransferase levels to 1,3-(2-chloroethyl)-1-nitrosourea chemotherapy in glioma patients. Neurosurg Focus. 1998;4(6):e3doi: 10.3171/foc.1998.4.4.4.
Chen, Z. P., Yarosh, D., Garcia, Y., Tampieri, D., Mohr, G., Langleben, A., & Panasci, L. C. (1998). Clinical response of O(6)-methylguanine-DNA methyltransferase levels to 1,3-(2-chloroethyl)-1-nitrosourea chemotherapy in glioma patients. Neurosurgical focus, 4(6), e3. https://doi.org/10.3171/foc.1998.4.4.4
Chen, Z P, et al. "Clinical response of O(6)-methylguanine-DNA methyltransferase levels to 1,3-(2-chloroethyl)-1-nitrosourea chemotherapy in glioma patients." Neurosurgical focus vol. 4,6 (1998): e3. doi: https://doi.org/10.3171/foc.1998.4.4.4
Chen ZP, Yarosh D, Garcia Y, Tampieri D, Mohr G, Langleben A, Panasci LC. Clinical response of O(6)-methylguanine-DNA methyltransferase levels to 1,3-(2-chloroethyl)-1-nitrosourea chemotherapy in glioma patients. Neurosurg Focus. 1998 Jun 15;4(6):e3. doi: 10.3171/foc.1998.4.4.4. PMID: 17154443.
Copy Download .nbib Format: NLM
Measurement of O-6-methylguanine-DNA methyltransferase activity using oligonucleotides and restriction enzyme in human brain tumors.

International journal of oncology

Yanagisawa T, Watanabe K, Mineura K, Kowada M.
PMID: 21541583
Int J Oncol. 1996 Oct;9(4):781-6. doi: 10.3892/ijo.9.4.781.

We determined the levels of MGMT activity in 46 human brain tumors, using oligonucleotides containing O-6-methylguanine at a PvuII recognition site, and correlated MGMT activity with chemotherapeutic effectiveness in 14 patients with high-grade gliomas who received ACNU chemotherapy. The...

Cite
Yanagisawa T, Watanabe K, Mineura K, et al. Measurement of O-6-methylguanine-DNA methyltransferase activity using oligonucleotides and restriction enzyme in human brain tumors. Int J Oncol. 1996;9(4):781-6doi: 10.3892/ijo.9.4.781.
Yanagisawa, T., Watanabe, K., Mineura, K., & Kowada, M. (1996). Measurement of O-6-methylguanine-DNA methyltransferase activity using oligonucleotides and restriction enzyme in human brain tumors. International journal of oncology, 9(4), 781-6. https://doi.org/10.3892/ijo.9.4.781
Yanagisawa, T, et al. "Measurement of O-6-methylguanine-DNA methyltransferase activity using oligonucleotides and restriction enzyme in human brain tumors." International journal of oncology vol. 9,4 (1996): 781-6. doi: https://doi.org/10.3892/ijo.9.4.781
Yanagisawa T, Watanabe K, Mineura K, Kowada M. Measurement of O-6-methylguanine-DNA methyltransferase activity using oligonucleotides and restriction enzyme in human brain tumors. Int J Oncol. 1996 Oct;9(4):781-6. doi: 10.3892/ijo.9.4.781. PMID: 21541583.
Copy Download .nbib Format: NLM
Current trends in targeted therapies for glioblastoma multiforme.

Neurology research international

Ohka F, Natsume A, Wakabayashi T.
PMID: 22530127
Neurol Res Int. 2012;2012:878425. doi: 10.1155/2012/878425. Epub 2012 Mar 05.

Glioblastoma multiforme (GBM) is one of the most frequently occurring tumors in the central nervous system and the most malignant tumor among gliomas. Despite aggressive treatment including surgery, adjuvant TMZ-based chemotherapy, and radiotherapy, GBM still has a dismal prognosis:...

Cite
Ohka F, Natsume A, Wakabayashi T. Current trends in targeted therapies for glioblastoma multiforme. Neurol Res Int. 2012;2012:878425doi: 10.1155/2012/878425.
Ohka, F., Natsume, A., & Wakabayashi, T. (2012). Current trends in targeted therapies for glioblastoma multiforme. Neurology research international, 2012878425. https://doi.org/10.1155/2012/878425
Ohka, Fumiharu, et al. "Current trends in targeted therapies for glioblastoma multiforme." Neurology research international vol. 2012 (2012): 878425. doi: https://doi.org/10.1155/2012/878425
Ohka F, Natsume A, Wakabayashi T. Current trends in targeted therapies for glioblastoma multiforme. Neurol Res Int. 2012;2012:878425. doi: 10.1155/2012/878425. Epub 2012 Mar 05. PMID: 22530127; PMCID: PMC3317017.
Copy Download .nbib Format: NLM
Preclinical evaluation of an O(6)-methylguanine-DNA methyltransferase-siRNA/liposome complex administered by convection-enhanced delivery to rat and porcine brains.

American journal of translational research

Tsujiuchi T, Natsume A, Motomura K, Kondo G, Ranjit M, Hachisu R, Sugimura I, Tomita S, Takehara I, Woolley M, Barua NU, Gill SS, Bienemann AS, Yamashita Y, Toyokuni S, Wakabayashi T.
PMID: 24489997
Am J Transl Res. 2014 Jan 15;6(2):169-78. eCollection 2014.

The main determinant of glioblastoma (GBM) resistance to temozolomide (TMZ) is thought to be O(6)-methylguanine-DNA methyltransferase (MGMT), which is a DNA-repair enzyme that removes alkyl groups from the O(6)-position of guanine. Previously, we reported that a MGMT-siRNA/cationic liposome complex...

Cite
Tsujiuchi T, Natsume A, Motomura K, et al. Preclinical evaluation of an O(6)-methylguanine-DNA methyltransferase-siRNA/liposome complex administered by convection-enhanced delivery to rat and porcine brains. Am J Transl Res. 2014;6(2):169-78
Tsujiuchi, T., Natsume, A., Motomura, K., Kondo, G., Ranjit, M., Hachisu, R., Sugimura, I., Tomita, S., Takehara, I., Woolley, M., Barua, N. U., Gill, S. S., Bienemann, A. S., Yamashita, Y., Toyokuni, S., & Wakabayashi, T. (2014). Preclinical evaluation of an O(6)-methylguanine-DNA methyltransferase-siRNA/liposome complex administered by convection-enhanced delivery to rat and porcine brains. American journal of translational research, 6(2), 169-78.
Tsujiuchi, Takashi, et al. "Preclinical evaluation of an O(6)-methylguanine-DNA methyltransferase-siRNA/liposome complex administered by convection-enhanced delivery to rat and porcine brains." American journal of translational research vol. 6,2 (2014): 169-78.
Tsujiuchi T, Natsume A, Motomura K, Kondo G, Ranjit M, Hachisu R, Sugimura I, Tomita S, Takehara I, Woolley M, Barua NU, Gill SS, Bienemann AS, Yamashita Y, Toyokuni S, Wakabayashi T. Preclinical evaluation of an O(6)-methylguanine-DNA methyltransferase-siRNA/liposome complex administered by convection-enhanced delivery to rat and porcine brains. Am J Transl Res. 2014 Jan 15;6(2):169-78. eCollection 2014. PMID: 24489997; PMCID: PMC3902228.
Copy Download .nbib Format: NLM
Metronomic treatment of temozolomide increases anti-angiogenicity accompanied by down-regulated O(6)-methylguanine-DNA methyltransferase expression in endothelial cells.

Experimental and therapeutic medicine

Ko KK, Lee ES, Joe YA, Hong YK.
PMID: 22977508
Exp Ther Med. 2011 Mar;2(2):343-348. doi: 10.3892/etm.2011.207. Epub 2011 Jan 20.

Metronomic chemotherapy is a continuous low-dose administration of chemotherapeutic agents to minimize toxicity and target tumor-associated endothelial cells. This therapy is beneficial to anti-angiogenic efficacy which is linked to the inhibition of tumor growth. In the present study, we...

Cite
Ko KK, Lee ES, Joe YA, et al. Metronomic treatment of temozolomide increases anti-angiogenicity accompanied by down-regulated O(6)-methylguanine-DNA methyltransferase expression in endothelial cells. Exp Ther Med. 2011;2(2):343-348doi: 10.3892/etm.2011.207.
Ko, K. K., Lee, E. S., Joe, Y. A., & Hong, Y. K. (2011). Metronomic treatment of temozolomide increases anti-angiogenicity accompanied by down-regulated O(6)-methylguanine-DNA methyltransferase expression in endothelial cells. Experimental and therapeutic medicine, 2(2), 343-348. https://doi.org/10.3892/etm.2011.207
Ko, Kyung-Kon, et al. "Metronomic treatment of temozolomide increases anti-angiogenicity accompanied by down-regulated O(6)-methylguanine-DNA methyltransferase expression in endothelial cells." Experimental and therapeutic medicine vol. 2,2 (2011): 343-348. doi: https://doi.org/10.3892/etm.2011.207
Ko KK, Lee ES, Joe YA, Hong YK. Metronomic treatment of temozolomide increases anti-angiogenicity accompanied by down-regulated O(6)-methylguanine-DNA methyltransferase expression in endothelial cells. Exp Ther Med. 2011 Mar;2(2):343-348. doi: 10.3892/etm.2011.207. Epub 2011 Jan 20. PMID: 22977508; PMCID: PMC3440646.
Copy Download .nbib Format: NLM
Quantitative detection of .

Oncology letters

Duppel U, Woenckhaus M, Schulz C, Merk J, Dietmaier W.
PMID: 27698890
Oncol Lett. 2016 Oct;12(4):3004-3012. doi: 10.3892/ol.2016.4927. Epub 2016 Aug 01.

Aberrant promoter methylation of tumor relevant genes frequently occurs in early steps of carcinogenesis and during tumor progression. Epigenetic alterations could be used as potential biomarkers for early detection and for prediction of prognosis and therapy response in lung...

Cite
Duppel U, Woenckhaus M, Schulz C, et al. Quantitative detection of . Oncol Lett. 2016;12(4):3004-3012doi: 10.3892/ol.2016.4927.
Duppel, U., Woenckhaus, M., Schulz, C., Merk, J., & Dietmaier, W. (2016). Quantitative detection of . Oncology letters, 12(4), 3004-3012. https://doi.org/10.3892/ol.2016.4927
Duppel, Uta, et al. "Quantitative detection of ." Oncology letters vol. 12,4 (2016): 3004-3012. doi: https://doi.org/10.3892/ol.2016.4927
Duppel U, Woenckhaus M, Schulz C, Merk J, Dietmaier W. Quantitative detection of . Oncol Lett. 2016 Oct;12(4):3004-3012. doi: 10.3892/ol.2016.4927. Epub 2016 Aug 01. PMID: 27698890; PMCID: PMC5038372.
Copy Download .nbib Format: NLM
Aberrant SOCS3 Promoter Methylation as a Noninvasive Diagnostic Biomarker for Locally Advanced Prostate Cancer.

Medeniyet medical journal

Demircan Tan B, Turan T, Yucel B, Altundag Kara S, Salman Yilmaz S, Yildirim A.
PMID: 32733758
Medeni Med J. 2020;35(2):99-105. doi: 10.5222/MMJ.2020.58708. Epub 2020 Jun 30.

OBJECTIVE: The aim of this study was to investigate the promoter methylation status of Rasassociated domain family 1A (RASSF1A), O-6-methylguanine-DNA methyltransferase (MGMT), Phosphatase with tensin homology (PTEN) and Suppressor of cytokine signaling 3 (SOCS3) tumor suppressor genes and evaluate...

Cite
Demircan Tan B, Turan T, Yucel B, et al. Aberrant SOCS3 Promoter Methylation as a Noninvasive Diagnostic Biomarker for Locally Advanced Prostate Cancer. Medeni Med J. 2020;35(2):99-105doi: 10.5222/MMJ.2020.58708.
Demircan Tan, B., Turan, T., Yucel, B., Altundag Kara, S., Salman Yilmaz, S., & Yildirim, A. (2020). Aberrant SOCS3 Promoter Methylation as a Noninvasive Diagnostic Biomarker for Locally Advanced Prostate Cancer. Medeniyet medical journal, 35(2), 99-105. https://doi.org/10.5222/MMJ.2020.58708
Demircan Tan, Berna, et al. "Aberrant SOCS3 Promoter Methylation as a Noninvasive Diagnostic Biomarker for Locally Advanced Prostate Cancer." Medeniyet medical journal vol. 35,2 (2020): 99-105. doi: https://doi.org/10.5222/MMJ.2020.58708
Demircan Tan B, Turan T, Yucel B, Altundag Kara S, Salman Yilmaz S, Yildirim A. Aberrant SOCS3 Promoter Methylation as a Noninvasive Diagnostic Biomarker for Locally Advanced Prostate Cancer. Medeni Med J. 2020;35(2):99-105. doi: 10.5222/MMJ.2020.58708. Epub 2020 Jun 30. PMID: 32733758; PMCID: PMC7384502.
Copy Download .nbib Format: NLM
Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma.

Molecular oncology

Gallon J, Coto-Llerena M, Ercan C, Bianco G, Paradiso V, Nuciforo S, Taha-Melitz S, Meier MA, Boldanova T, Pérez-Del-Pulgar S, Rodríguez-Tajes S, von Flüe M, Soysal SD, Kollmar O, Llovet JM, Villanueva A, Terracciano LM, Heim MH, Ng CKY, Piscuoglio S.
PMID: 34863035
Mol Oncol. 2021 Dec 04; doi: 10.1002/1878-0261.13154. Epub 2021 Dec 04.

Hepatocellular carcinomas (HCCs) usually arise from chronic liver disease (CLD). Precancerous cells in chronically inflamed environments may be 'epigenetically primed', sensitising them to oncogenic transformation. We investigated whether epigenetic priming in CLD may affect HCC outcomes by influencing the...

Cite
Gallon J, Coto-Llerena M, Ercan C, et al. Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma. Mol Oncol. 2021;doi: 10.1002/1878-0261.13154.
Gallon, J., Coto-Llerena, M., Ercan, C., Bianco, G., Paradiso, V., Nuciforo, S., Taha-Melitz, S., Meier, M. A., Boldanova, T., Pérez-Del-Pulgar, S., Rodríguez-Tajes, S., von Flüe, M., Soysal, S. D., Kollmar, O., Llovet, J. M., Villanueva, A., Terracciano, L. M., Heim, M. H., Ng, C. K. Y., & Piscuoglio, S. (2021). Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma. Molecular oncology, . https://doi.org/10.1002/1878-0261.13154
Gallon, John, et al. "Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma." Molecular oncology vol. (2021). doi: https://doi.org/10.1002/1878-0261.13154
Gallon J, Coto-Llerena M, Ercan C, Bianco G, Paradiso V, Nuciforo S, Taha-Melitz S, Meier MA, Boldanova T, Pérez-Del-Pulgar S, Rodríguez-Tajes S, von Flüe M, Soysal SD, Kollmar O, Llovet JM, Villanueva A, Terracciano LM, Heim MH, Ng CKY, Piscuoglio S. Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma. Mol Oncol. 2021 Dec 04; doi: 10.1002/1878-0261.13154. Epub 2021 Dec 04. PMID: 34863035.
Copy Download .nbib Format: NLM
Targeted methylation facilitates DNA double strand breaks and enhances cancer suppression: A DNA intercalating/methylating dual-action chimera Amonafidazene.

European journal of medicinal chemistry

Walunj D, Thankarajan E, Prasad C, Tuchinsky H, Baldan S, Sherman MY, Patsenker L, Gellerman G.
PMID: 34507011
Eur J Med Chem. 2021 Dec 05;225:113811. doi: 10.1016/j.ejmech.2021.113811. Epub 2021 Aug 31.

A DNA intercalating agent Amonafide interferes with topoisomerase 2 (Topo II) activity and prevents re-ligation of DNA strands, leading to double strand breaks (DSB). If DSB repair fails, cells stop dividing and eventually die. In a search of approaches...

Cite
Walunj D, Thankarajan E, Prasad C, et al. Targeted methylation facilitates DNA double strand breaks and enhances cancer suppression: A DNA intercalating/methylating dual-action chimera Amonafidazene. Eur J Med Chem. 2021;225:113811doi: 10.1016/j.ejmech.2021.113811.
Walunj, D., Thankarajan, E., Prasad, C., Tuchinsky, H., Baldan, S., Sherman, M. Y., Patsenker, L., & Gellerman, G. (2021). Targeted methylation facilitates DNA double strand breaks and enhances cancer suppression: A DNA intercalating/methylating dual-action chimera Amonafidazene. European journal of medicinal chemistry, 225113811. https://doi.org/10.1016/j.ejmech.2021.113811
Walunj, Dipak, et al. "Targeted methylation facilitates DNA double strand breaks and enhances cancer suppression: A DNA intercalating/methylating dual-action chimera Amonafidazene." European journal of medicinal chemistry vol. 225 (2021): 113811. doi: https://doi.org/10.1016/j.ejmech.2021.113811
Walunj D, Thankarajan E, Prasad C, Tuchinsky H, Baldan S, Sherman MY, Patsenker L, Gellerman G. Targeted methylation facilitates DNA double strand breaks and enhances cancer suppression: A DNA intercalating/methylating dual-action chimera Amonafidazene. Eur J Med Chem. 2021 Dec 05;225:113811. doi: 10.1016/j.ejmech.2021.113811. Epub 2021 Aug 31. PMID: 34507011.
Copy Download .nbib Format: NLM
Presentation of treatment effect in glioblastoma after dose-escalation radiation therapy.

Oxford medical case reports

Cicka D, Ford CL, Templin E, Pitts Z, Gurbani S, Eaton B, Lowder L, Olson J, Weinberg BD, Shim H, Sengupta S.
PMID: 31772751
Oxf Med Case Reports. 2019 Sep 28;2019(9):omz085. doi: 10.1093/omcr/omz085. eCollection 2019 Sep.

Glioblastoma is the most aggressive primary brain tumor in adults. Limited treatment options and the intense nature of therapy make determining the appropriate treatment course for each patient difficult. The appearance of transient worsening of imaging findings, known as...

Cite
Cicka D, Ford CL, Templin E, et al. Presentation of treatment effect in glioblastoma after dose-escalation radiation therapy. Oxf Med Case Reports. 2019;2019(9):omz085doi: 10.1093/omcr/omz085.
Cicka, D., Ford, C. L., Templin, E., Pitts, Z., Gurbani, S., Eaton, B., Lowder, L., Olson, J., Weinberg, B. D., Shim, H., & Sengupta, S. (2019). Presentation of treatment effect in glioblastoma after dose-escalation radiation therapy. Oxford medical case reports, 2019(9), omz085. https://doi.org/10.1093/omcr/omz085
Cicka, Danielle, et al. "Presentation of treatment effect in glioblastoma after dose-escalation radiation therapy." Oxford medical case reports vol. 2019,9 (2019): omz085. doi: https://doi.org/10.1093/omcr/omz085
Cicka D, Ford CL, Templin E, Pitts Z, Gurbani S, Eaton B, Lowder L, Olson J, Weinberg BD, Shim H, Sengupta S. Presentation of treatment effect in glioblastoma after dose-escalation radiation therapy. Oxf Med Case Reports. 2019 Sep 28;2019(9):omz085. doi: 10.1093/omcr/omz085. eCollection 2019 Sep. PMID: 31772751; PMCID: PMC6765376.
Copy Download .nbib Format: NLM
Extent of Resection, MGMT Promoter Methylation Status and Tumor Location Independently Predict Progression-Free Survival in Adult Sporadic Pilocytic Astrocytoma.

Cancers

Jungk C, Reinhardt A, Warta R, Capper D, Deimling AV, Herold-Mende C, Unterberg A.
PMID: 31362435
Cancers (Basel). 2019 Jul 29;11(8). doi: 10.3390/cancers11081072.

In adults, pilocytic astrocytomas (PA) account for less than 2% of gliomas, resulting in uncertainty regarding the clinical course and optimal treatment, particularly in cases where gross total resection (GTR) could not be achieved. Moreover, information on molecular markers...

Cite
Jungk C, Reinhardt A, Warta R, et al. Extent of Resection, MGMT Promoter Methylation Status and Tumor Location Independently Predict Progression-Free Survival in Adult Sporadic Pilocytic Astrocytoma. Cancers (Basel). 2019;11(8)doi: 10.3390/cancers11081072.
Jungk, C., Reinhardt, A., Warta, R., Capper, D., Deimling, A. V., Herold-Mende, C., & Unterberg, A. (2019). Extent of Resection, MGMT Promoter Methylation Status and Tumor Location Independently Predict Progression-Free Survival in Adult Sporadic Pilocytic Astrocytoma. Cancers, 11(8), . https://doi.org/10.3390/cancers11081072
Jungk, Christine, et al. "Extent of Resection, MGMT Promoter Methylation Status and Tumor Location Independently Predict Progression-Free Survival in Adult Sporadic Pilocytic Astrocytoma." Cancers vol. 11,8 (2019). doi: https://doi.org/10.3390/cancers11081072
Jungk C, Reinhardt A, Warta R, Capper D, Deimling AV, Herold-Mende C, Unterberg A. Extent of Resection, MGMT Promoter Methylation Status and Tumor Location Independently Predict Progression-Free Survival in Adult Sporadic Pilocytic Astrocytoma. Cancers (Basel). 2019 Jul 29;11(8). doi: 10.3390/cancers11081072. PMID: 31362435; PMCID: PMC6721291.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 66 entries